Pfizer (PFE) Research & Development (2009 - 2026)

Pfizer (PFE) has 18 years of Research & Development data on file, last reported at $2.5 billion in Q1 2026.

• Research & Development for Q1 2026 came in at $2.5 billion, up 13.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.7 billion (up 7.35% YoY), and the FY2025 annual result was $10.4 billion, down 3.56% from the prior year.
• Research & Development slipped to $2.5 billion in Q1 2026 per PFE's latest filing, from $3.2 billion in the prior quarter.
• Over five years, Research & Development peaked at $3.2 billion in Q4 2025 and troughed at $2.2 billion in Q1 2025.
• A 5-year average of $2.6 billion and a median of $2.6 billion in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development climbed 25.73% in 2022, then declined 11.63% in 2025.
• A 5-year view of Research & Development shows it stood at $2.7 billion in 2022, then gained by 4.41% to $2.8 billion in 2023, then fell by 7.71% to $2.6 billion in 2024, then increased by 23.4% to $3.2 billion in 2025, then decreased by 22.33% to $2.5 billion in 2026.
• Business Quant data shows PFE's Research & Development at $2.5 billion in Q1 2026, $3.2 billion in Q4 2025, and $2.5 billion in Q3 2025.